Brief: Santhera Says Submits Marketing Authorization Application To European Medicines Agency For Vamorolone In Duchenne Muscular Dystrophy
03/10/2022 06:10
Oct 3 (Reuters) - Santhera Pharmaceuticals Holding AG
SANN.S :
* SANTHERA - SUBMITS MARKETING AUTHORIZATION APPLICATION TO
EUROPEAN MEDICINES AGENCY FOR VAMOROLONE IN DUCHENNE MUSCULAR
DYSTROPHY
Source text for Eikon: ID:
Further company coverage: SANN.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Santhera Pharmaceuticals Holding AG
See all newsSwitzerland's Santhera Pharma H1 revenue soars on AGAMREE sales, milestones
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -6.562 Million
Brief: Santhera Says NXERA Plans To Submit South Korea Marketing Authorization Application 2026
Brief: Santhera Gets Positive CHMP Opinion To Expand Agamree (Vamorolone) Use
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -35.444 Million